Make your own free website on Tripod.com

Young People Get Osteoporosis Too 

Butterfly1b1  AREDIAButterfly1b5

Home • Up • SITE MAP • MY STORY • FAQ'S • DEXA SCANS • DIAGNOSIS • TREATMENT • DIET • EXERCISE • CALCIUM • VITAMIN D • DRUGS IN DEVELOPMENT • RESEARCH • NEWLY DIAGNOSED • ALTERNATIVES • FRACTURES • KYPHOPLASTY • VERTEBROPLASTY • RELATED DISORDERS • MISC INFO • ASK A DOCTOR • MYTHS • OSTEOPOROSIS FACTS • GLOSSARY • ARTICLES • LINKS • ADVOCACY • SUPPORT GROUP • AWARDS


Free E Cards • Email

 

 

DISCLAIMER:

Please be advised that the inclusion of any medication on this site is not indicative of an endorsement.  I do not have any affiliation with the pharmaceutical corporations that manufacture prescription osteoporosis medications.  I am not a doctor, therefore I am not medically qualified to counsel or advise osteoporosis patients about which medication is best suited for their individual case.

• actonel • aredia • boniva • didronel • evista • Forteo • fosamax • miacalcin • zometa • vivelle • reclast •

Aredia (Pamidronate) is used, along with cancer therapy, in patients with breast cancer or multiple myeloma whose disease has spread to the bones. The effect of Aredia appeared to be less in breast cancer patients receiving hormonal therapy than in those receiving chemotherapy, though clinical benefit has been shown. 

Aredia can help in two important ways:

1) Aredia helps reduce the chance of bone complications that include fractures, surgery to bone, and radiation to bone. Aredia can be effective in treating your bone complications, whether or not you have already experienced problems

2) Aredia can decrease bone pain in some breast cancer and multiple myeloma patients. Studies have also shown that some people needed fewer doses or a lower strength of pain medication; others were able to switch from narcotics to over-the-counter pain relievers. Understanding the studies that have shown a reduction in bone pain and in use of pain medication can be complicated because many tests were performed. Your doctor is the best resource for help in understanding how these study results relate to your cancer.

Aredia is the only medication designed to specifically delay and reduce the complications caused by cancer that has spread to the bone and the pain that comes with it. Aredia was tested in over 1100 patients with bone metastases. The results showed that patients who were given Aredia had fewer bone complications and some had less bone pain. Some patients who already had bone complications before starting Aredia had fewer new bone problems during treatment.

Some Aredia patients may experience fever, fatigue, nausea, vomiting, bone pain, lack of appetite, which pass in a few days, and anemia. Your doctor can recommend a mild pain reliever that may help prevent these symptoms or relieve them if they occur. You should talk to your doctor if you experience high temperature, redness, swelling, or pain at the site where Aredia is infused, tiredness, nausea, lack of appetite, or muscle twitching. Your doctor will be checking your blood routinely for anemia and other possible side effects and will be watching your response to this medication.

Aredia is treatment for cancer that has spread to your bones, called bone metastases.

The dual benefits of Aredia are delay and reduction of bone complications, such as fractures, and the possibility of reducing bone pain. The only medication approved for the treatment of bone metastases, Aredia is clinically proven to be effective. Aredia is not chemotherapy and can be taken along with other cancer treatments. If you have any questions about Aredia, ask your doctor

Another way to reduce the likelihood of having bone complications is to use intravenous bisphosphonates. Bisphosphonates are drugs that affect the process by which bone is lost. Bisphosphonates are administered in addition to other anti-cancer therapies. Intravenous Aredia (pamidronate disodium for injection) is the only bisphosphonate that is approved for the treatment of osteolytic lesions caused by breast cancer and multiple myeloma. It is used along with other cancer therapies.


Pamidronate Appears to Reduce Osteoclast Activity and Bone Resorption in Thalassaemic Osteoporosis


Pamidronate effectively reduced osteoclast activity and bone resorption, and lead to increased lumbar bone mineral density in patients with beta-thalassaemia, report researchers from Greece.

Although treatment has increased life expectancy in this population, serious complications including osteoporosis often occur, caused in part by increased osteoclast function. Studies have shown varied results with the use of bisphosphonates to treat osteoporosis in patients with beta-thalassaemia. Oral alendronate has been associated with increased bone mineral density (BMD), no beneficial effect has been noted with clodronate and, to date, no good evidence is available on the use of pamidronate in this setting.

To evaluate the effect of pamidronate on osteoporosis in patients with beta-thalassaemia, Ersi Voskaridou, MD, Laikon General Hospital, Athens, and colleagues administered 30 mg/month pamidronate to 18 patients (13 dependent on transfusion; 5 never transfused or occasionally transfused) or 60 mg/month pamidronate to 8 patients (4 regularly transfused; 4 occasionally transfused). All patients had beta-thalassaemia with osteoporosis. A control group of 30 of healthy blood donors, matched by age and sex to the treatment groups, was used for comparison. Evaluation of the effect of pamidronate on bone remodelling, osteoclast function, and bone mineral density was done using basic and all bone-related biochemical tests (NTX, TRACP-5b, bALP, OC, OPG, and sRANKL).

Regardless of transfusion status or dose group, all treated patients had significantly higher NTX, TRACP-5b, bALP, and OC values than participants in the control group (P < .0005, P < .0005, P > .01, P < .04, respectively). The control group, on the other hand, had significantly higher OPG values than did the treatment groups (P < .001). Variation in the sRANKL levels remained in normal levels for all groups. Dose did not significantly effect these values between the treatment groups. In addition, dose nor transfusion status altered the effect of pamidronate on BMD of the lumbar spine, with significant increases in the BMD of the lumbar spine found for all treated patients (but not for the BMD of the femoral neck or forearm).

The comparable beneficial effects of 30 mg and 60 mg/month of pamidronate found in this study, along with the reported good compliance and drug tolerability, led the authors to conclude that 30 mg/month regimen of pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.

British Journal of Haematology 2003;123:730-737. "Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia"

IMPORTANT SAFETY INFORMATION

AREDIA (pamidronate disodium) is contraindicated in patients with clinically significant hypersensitivity to bisphosphonates or any of the excipients in the formulation.

Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of AREDIA (pamidronate disodium) should not exceed 90 mg and the duration of infusion should be no less than 2 hours. Risk factors for the deterioration of renal function include elevated baseline creatinine and multiple cycles of bisphosphonate treatment.

AREDIA (pamidronate disodium) is not recommended in patients with severe renal impairment. Serum creatinine should be measured before each dose and treatment should be withheld for renal deterioration. In the clinical studies, patients with serum creatinine >3.0 mg/dL were excluded, renal deterioration was defined as an increase of 0.5 mg/dL for patients t with normal baseline creatinine and an increase of 1.0 mg/dL for patients with abnormal baseline creatinine. Treatment was resumed only when the creatinine returned to within 10% of the baseline value.

AREDIA (pamidronate disodium) is excreted intact primarily via the kidney, and the risk of renal adverse reactions may be greater in patients with impaired renal function. Patients who receive AREDIA (pamidronate disodium) should have serum creatinine assessed prior to each treatment. In patients receiving AREDIA (pamidronate disodium) for bone metastases, who show evidence of deterioration in renal function, AREDIA (pamidronate disodium) treatment should be withheld until renal function returns to baseline.

Pregnancy Category D. AREDIA (pamidronate disodium) should not be used during pregnancy. Women of childbearing potential should be advised to avoid becoming pregnant. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

Osteonecrosis of the Jaw (ONJ) has been reported in patients with cancer receiving treatment including bisphosphonates, chemotherapy, and/or corticosteroids. The majority of reported cases have been associated with dental procedures such as tooth extraction. A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors. While on treatment, these patients should avoid invasive dental procedures if possible. No data are available as to whether discontinuation of bisphosphonate therapy reduces the risk of ONJ in patients requiring dental procedures.

The most common adverse events in bone metastases clinical trials regardless of causality were as follows: Fluid overload, generalized pain, hypertension, abdominal pain, anorexia, constipation, nausea, vomiting, urinary tract infection, bone pain, fever, back pain, arthrosis, headache, anemia, hypocalcemia, arthralgias, myalgias, and dyspnea.

 

 

 


top of page

 

Young People Get Osteoporosis Too Organization
Copyright 2001  All rights reserved.
Revised: 03/11/08.